Alnylam Pharmaceuticals, Inc. (ALNY) Upgraded at Vetr Inc.

Vetr upgraded shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from a strong sell rating to a strong-buy rating in a research report sent to investors on Thursday. They currently have $72.50 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the stock. FBR & Co reiterated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 7th. Needham & Company LLC reissued a buy rating and issued a $68.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 9th. JMP Securities set a $69.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a research report on Friday, February 3rd. Ladenburg Thalmann Financial Services began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 2nd. They issued a buy rating and a $75.00 price objective on the stock. Finally, Chardan Capital increased their price objective on shares of Alnylam Pharmaceuticals from $69.00 to $97.00 and gave the company a buy rating in a research report on Monday, January 9th. Seven analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $64.53.

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 59.71 on Thursday. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $80.11. The firm’s market capitalization is $5.14 billion. The stock’s 50 day moving average is $47.17 and its 200 day moving average is $48.26.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.02. The firm earned $17.50 million during the quarter, compared to analysts’ expectations of $10.66 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The company’s revenue for the quarter was up 130.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.07) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.08) earnings per share for the current fiscal year.

Your IP Address:

In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction dated Wednesday, January 25th. The shares were sold at an average price of $37.95, for a total transaction of $569,250.00. Following the sale, the director now directly owns 155,795 shares in the company, valued at $5,912,420.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.00% of the company’s stock.

A number of large investors have recently made changes to their positions in the company. Mn Services Vermogensbeheer B.V. increased its stake in shares of Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 87 shares during the last quarter. Neuberger Berman Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $205,000. Notis McConarty Edward purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $229,000. Hall Laurie J Trustee purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $160,000. Finally, Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $266,000. Hedge funds and other institutional investors own 88.70% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

5 Day Chart for NASDAQ:ALNY

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.